Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 482

Related Citations for PubMed (Select 15020310)

1.

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A.

Ann Rheum Dis. 2004 Nov;63(11):1419-26. Epub 2004 Feb 27.

2.

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.

Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.

Curr Med Res Opin. 2005 Apr;21(4):517-26.

PMID:
15899100
3.
4.

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.

Clin Rheumatol. 2006 Feb;25(1):42-53. Epub 2005 Aug 13.

PMID:
16132165
5.

Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.

Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A.

Clin Exp Rheumatol. 2004 Sep-Oct;22(5):589-96.

PMID:
15485012
6.

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY.

BMC Musculoskelet Disord. 2008 Mar 7;9:32. doi: 10.1186/1471-2474-9-32.

7.
8.

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U.

Arthritis Res Ther. 2006;8(2):R35. Epub 2006 Jan 16.

9.

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poór G.

Arthritis Rheum. 2004 Aug 15;51(4):549-57.

10.

Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.

Bitner M, Kattenhorn J, Hatfield C, Gao J, Kellstein D.

Int J Clin Pract. 2004 Apr;58(4):340-5.

PMID:
15161117
13.

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.

Rheumatology (Oxford). 2007 Mar;46(3):496-507. Epub 2006 Aug 27.

14.

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M.

Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.

15.

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.

Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, Maxwell T.

Clin Rheumatol. 2011 Nov;30(11):1433-46. doi: 10.1007/s10067-011-1776-4. Epub 2011 May 24.

PMID:
21607551
16.
17.
18.

Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients.

Kim J, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Lee YJ, Ryu H, Lee KH, Song YW.

Clin Ther. 2009 Dec;31(12):2860-72. doi: 10.1016/j.clinthera.2009.12.016.

PMID:
20110025
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk